Syndromic testing – the future of molecular diagnostics
Syndromic testing with the QIAstat-Dx system allows you to rapidly and simultaneously survey a large number of pathogens in a single sample. This means you can get comprehensive diagnostic answers in around an hour. And patients can get the right treatment faster.
To learn more about the benefits of QIAstat-Dx syndromic testing and hear about the latest insights on molecular diagnostics for infectious disease, watch our most recent webinars.
Watch the webinars
-
Learn about the clinical outcomes of using dry swabs for respiratory syndromic testing
Title: The clinical outcomes of using dry swabs for respiratory syndromic testing
Speaker: Donia Bouzid, MD, PhD, Bichat Claude-Bernard Hospital, Emergency Department, FranceThis webinar discusses how multiplex syndromic testing using dry swab samples has positively impacted clinical decision making in a hospital in Paris, France. Dr. Donia Bouzid describes how prior to adopting multiplex PCR, Bichat Claude-Bernard Hospital experienced long wait times between the arrival of patients at the hospital and the diagnosis of respiratory infections. She then discusses how the faster turnaround time and comprehensive results provided by syndromic testing with the QIAstat-Dx Analyzer have influenced clinical outcomes at the hospital, including positively impacting single room assignment.
-
Learn about the role of multiplex testing in the COVID-19 pandemic
Title: Tackling COVID-19 through syndromic testing – QIAstat-Dx Respiratory SARS-CoV-2
Speaker: Davide Manissero, MD, MRCPCH, MSc, DTM&H, VP Head of Medical Affairs & Chief Medical Officer, Infection & Immune Diagnostics, QIAGENDuring this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero will discuss the role of multiplex respiratory PCR testing in the ongoing COVID-19 pandemic and how QIAGEN ramped up development efforts to be the first syndromic solution on the market. The importance of time to diagnosis and potential for co-infections as we approach the 2020-2021 influenza season will be discussed.
-
Learn about the benefits of syndromic testing for acute respiratory illness
Title: A new multiplex syndromic system for respiratory diagnosis and improved patient care
Speaker: Dr. Steve Young, Director of Research and Clinical Trials, TriCore Reference LaboratoriesThis webinar discusses how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections. Acute respiratory tract infections are caused by a wide range of viral and bacterial pathogens and may share similar clinical presentations that make it difficult for physicians to diagnose based on symptoms alone. Syndromic testing with multiplex molecular panels offers clinical labs a way to quickly distinguish between a broad array of respiratory pathogens. In this webinar, Dr. Steve Young of Tricore Reference Laboratories presents a new technology for multiplexed respiratory testing in acutely ill patients. He shares data demonstrating the capabilities of syndromic respiratory testing as well as his impressions on the ease of doing comprehensive syndromic testing using the QIAstat-Dx Analyzer.
-
Learn about the clinical outcomes of using dry swabs for respiratory syndromic testing
-
Learn about the role of multiplex testing in the COVID-19 pandemic
-
Learn about the benefits of syndromic testing for acute respiratory illness
QIAstat-Dx resources and further reading
-
Go beyond fast resultsLearn how multiplex PCR testing offers a variety of benefits for healthcare institutions, including improved patient management and cost savings. -
Syndromic testing simplifiedSet your lab up for success with a streamlined syndromic test. The QIAstat-Dx panels redefine ease-of-use with less than one minute hands-on time and a seamless sample to result workflow. -
Get in touchContact the QIAGEN team to learn more about QIAstat-Dx syndromic testing or to place an order.
The QIAstat-Dx Analyzer and QIAstat-Dx Respiratory SARS-CoV-2 Panel are intended for in vitro diagnostic use.
Product availability and claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.